- Home
- ORIC
as 12-17-2024 4:00pm EST
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 633.7M | IPO Year: | 2020 |
| Target Price: | $18.75 | AVG Volume (30 days): | 294.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.33 - $16.65 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Multani Pratik S | ORIC | Chief Medical Officer | Dec 15 '24 | Sell | $8.28 | 8,850 | $73,293.05 | 46,765 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Dec 15 '24 | Sell | $8.28 | 24,660 | $204,214.39 | 778,648 |
Latest Oric Pharmaceuticals Inc. News
ORIC Breaking Stock News: Dive into ORIC Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
a month ago
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
GlobeNewswire
a month ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
2 months ago
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target
MT Newswires
2 months ago
Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target
GlobeNewswire
2 months ago
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Simply Wall St.
2 months ago
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Compare ORIC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.